Eylea Sales Continue to Increase; Lucentis Gains New Indications

August 11, 2017: By Joan McKenna

Lucentis and EyleaRegeneron reported that its Q2-2017 net sales of Eylea in the US totaled $919 million, an increase of 11 percent over Q2-2016 net sales of $831 million.

Bayer commercializes Eylea outside the US, and its Q2-2017 net sales of the anti-VEGF increased to $542 million, up 10 percent over $486 million in Q2-2016. Regeneron said it recognized $191 million from its share of Bayer’s Eylea sales, compared with $167 million in Q2-2016.

Roche reported that Lucentis’ Q2-2017 sales in the US totaled about $348 million (CHF $335 million, conversion Aug. 11, 2017), a 5 percent decline from Q2-2016 sales. Still, revenues for the retinal treatment were up 2 percent for the first half of the year at $755 million (CHF $727 million). Roche noted that Lucentis gained US FDA approval for all forms of diabetic retinopathy during the quarter.

Novartis sells Lucentis outside the US, and its Q2-2017 sales totaled $477 million, up 5 percent in constant currency but flat in US dollars. Novartis said Lucentis has gained added labeling for choroidal neovascularization in 51 countries, as well as Europe, where the indication was approved in 2016, and the Lucentis prefilled syringe has launched in 32 countries.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023